Back to Browse Journals » Core Evidence » Volume 5

Panitumumab: the evidence for its use in the treatment of metastatic colorectal cancer

Authors Rossana Berardi, Azzurra Onofri, Mirco Pistelli, et al

Published Date September 2010 Volume 2010:5 Pages 61—76

DOI http://dx.doi.org/10.2147/CE.S7035

Published 24 September 2010

Rossana Berardi1, Azzurra Onofri2, Mirco Pistelli2, Elena Maccaroni2, Mario Scartozzi1, Chiara Pierantoni1, Stefano Cascinu1
1Clinica di Oncologia Medica, Università Politecnica delle Marche, Ospedali Riuniti Umberto I-GM Lancisi-G Salesi di Ancona, Italy; 2Scuola di Specializzazione in Oncologia Medica, Università Politecnica delle Marche, Ancona, Italy

Abstract: Panitumumab is the first fully human monoclonal antibody to Epidermal Growth Factor Receptor (EGFR) to enter clinical trials for the treatment of solid tumors. The anti-tumor activity of panitumumab has been tested in vitro and in vivo, and inhibition of tumor growth has been observed in numerous cancer models, particularly lung, kidney and colorectal (CRC). Preclinical and clinical studies have established a role for panitumumab in metastatic colorectal cancer (mCRC) refractory to multiple chemotherapeutic regimens. Based on these encouraging findings, panitumumab was approved by the US Food and Drug Administration for the treatment of patients with epidermal growth factor receptor-expressing mCRC refractory to fluoropyrimidine-, oxaliplatin-, and/or irinotecan-containing chemotherapeutic regimens. The improvement in progression free survival (PFS) and response rate (RR) produced by panitumumab monotherapy was significantly greater in patients with non mutated (wild-type) K-RAS than in those with mutant K-RAS. Therefore implementing routine K-RAS screening and limiting the use of EGFR inhibitors to patients with wild-type K-RAS appears the better strategy for select only the patients who could benefit from the therapy with panitumumab and also may have the potential for cost savings. The purpose of this review was to evaluate the patient-related, disease-related and economic-related evidence for the use of panitumumab in the treatment of metastatic colorectal cancer in clinical practice.

Keywords: colorectal cancer, EGFR; K-RAS, panitumumab
 

Download Article [PDF] 

Creative Commons License This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php

Other article by this author:

Novel small molecule EGFR inhibitors as candidate drugs in non-small cell lung cancer

Berardi R, Santoni M, Morgese F, Ballatore Z, Savini A, Onofri A, Mazzanti P, Pistelli M, Pierantoni C, De Lisa M, Caramanti M, Pagliaretta S, Pellei C, Cascinu S

OncoTargets and Therapy 2013, 6:563-576

Published Date: 21 May 2013

Readers of this article also read:

Glycemic control and diabetes-related health care costs in type 2 diabetes; retrospective analysis based on clinical and administrative databases

Degli Esposti L, Saragoni S, Buda S, Sturani A, Degli Esposti E

ClinicoEconomics and Outcomes Research 2013, 5:193-201

Published Date: 14 May 2013

Insight into 144 patients with ocular vascular events during VEGF antagonist injections

Mansour AM, Shahin M, Kofoed PK, Parodi MB, Shami M, Schwartz SG

Clinical Ophthalmology 2012, 6:343-363

Published Date: 6 March 2012

Benefit of intravenous antibiotic therapy in patients referred for treatment of neurologic Lyme disease

Stricker RB, DeLong AK, Green CL, Savely VR, Chamallas SN, Johnson L

International Journal of General Medicine 2011, 4:639-646

Published Date: 6 September 2011

The role of galenic innovation in improving treatment compliance and persistence: three case studies

Zoellner Y, Balp MM, Gili Marco A

ClinicoEconomics and Outcomes Research 2011, 3:109-116

Published Date: 4 August 2011

Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine

Duncan RS, Xin H, Goad DL, Chapman KD, Koulen P

Clinical Ophthalmology 2011, 5:543-548

Published Date: 26 April 2011

Pitavastatin: evidence for its place in treatment of hypercholesterolemia

Peter Alagona, Jr

Core Evidence 2010, 5:91-105

Published Date: 22 October 2010

Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis

Eliana Krulig, Kenneth B Gordon

Core Evidence 2010, 5:11-22

Published Date: 5 July 2010

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors

Eduardo Pimenta, Suzanne Oparil

Vascular Health and Risk Management 2009, 5:453-463

Published Date: 19 May 2009

The cognitive impact of anticholinergics: A clinical review

Noll Campbell, Malaz Boustani, Tony Limbil, Carol Ott, et al.

Clinical Interventions in Aging 2009, 4:225-233

Published Date: 13 May 2009

Inflammatory mediators: Parallels between cancer biology and stem cell therapy

A Patel, Andrew C Heinrich, Bobby Y Reddy, Pranela Rameshwar

Journal of Inflammation Research 2009, 2:13-19

Published Date: 4 February 2009